Aston University study revisits WW1 'dazzle camouflage'
Warships camouflaged with zig-zags, swooping curves and bright bursts of colour became a regular sight during World War One. It sounds bizarre, drawing attention rather than trying to hide, but "dazzle camouflage" was a real idea used by both the US and Royal navies to try and fool German submarines.A team from Aston University in Birmingham has concluded that it could have helped to disguise a boat's movements, but in a lesser way to that foreseen by its inventors.The outlandish paintwork has also been overtaken by modern tracking using radar and sonar.
Prof Tim Meese and Dr Samantha Strong from Aston re-examined a 105 year-old experiment which represents the only attempt to try to understand the effectiveness of dazzle camouflage.They re-ran the experiment, carried out by Leo Blodgett, a young student at Massachusetts Institute of Technology (MIT) in the US. Leo used model ships on a canvas sea to try out various patterns and see what effect they had on those watching.
Dr Strong explained the point of dazzle "isn't to disguise the ship... rather you are disguising the ship's intention". While dazzle camouflage may even have drawn attention to the ship, the aim was to confuse an enemy captain's perception about its direction of travel - making it much harder to hit with a torpedo.Dazzle produces a "twist effect" according to Prof Meese, confusing onlookers into believing the ship is heading in a different direction to its real one. It is a real effect and this century-old experiment did find and measure it, but today's scientists believe there is a second, "horizon" effect.
Observers of a distant ship travelling along the horizon may think the ship is moving along the horizon itself, but it can actually be moving away from or towards the viewer by as much as 25 degrees."The twist effect was there but was much weaker than was perhaps thought back in the day," said Prof Meese. The horizon effect is much more important in disguising the ship's direction, the scientists concluded. Dazzle can work but it is quite a small effect on its own.In the end, technology put paid to dazzle camouflage, as tracking by sonar and radar came to the fore, and put an end to the intriguing experiment in camouflage.However, the Aston University scientists concluded that lone student Leo Blodgett demonstrated how a zig-zag, spotty and stripy paint job could have some value in protecting allied ships.
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
16 minutes ago
- Daily Mail
Spine zapper that means despite her paralysis, Sarra can now brush her daughter's hair again
Scaling Mount Snowdon would be an achievement for anyone. But for Sarra Wilson it's even more impressive. Sarra was paralysed from the chest down in September 2018, when she fell from her horse Lorenzo after he was startled by a pheasant as she rode across the family farm. Sarra broke the fifth vertebra in her neck – and her life changed in an instant. The accident left Sarra, 39, unable to walk, with minimal movement in her arms, hands and trunk – meaning even sitting around a table to enjoy a normal meal with her husband and three children was impossible. But now Sarra has regained some movement and sensation after taking part in a UK trial, described as a 'gamechanger' for the 110,000 in this country living with paralysis as a result of spinal-cord injury. Every year, around 4,700 people in the UK suffer a spinal-cord injury, with falls and road traffic accidents the leading causes – around 12 per cent are the result of an injury sustained during horse riding or rugby. 'Usually when the spinal cord [the nerves and tissue which carry impulses from the brain to the body] is injured, it's pinched or crushed rather than severed or torn because it's protected by the bony channel called the spinal canal,' explains David Baxter, a consultant neurosurgeon at the Whittington Hospital in London and associate professor at University College London, who was not involved in the trial. 'If you suffer a crush injury, the nerve fibres in the spine, called axons, which transmit electrical signals from the brain to the body and back again are damaged – which causes paralysis.' This 'primary' injury can also lead to bleeding and swelling in the spinal cord, which further reduces blood flow and worsens the extent of paralysis, leading to 'secondary' injury, adds Mr Baxter. 'As a result, a scar forms which makes it difficult to repair the nerve fibres, and there was little hope of improvement in these patients – until now.' For the new trial, called Pathfinder 2, ten participants, who had a chronic spinal injury at least a year before, which had left them paralysed, had electrodes attached to the skin on the back of their neck close to their injury site. These electrodes were then connected to an external device that delivers electrical stimulation set by a programme technician to each participant's injury and requirements – greater movement in their arms, for instance. At the same time, they carried out targeted rehab activities – such as stacking cups or gym-type exercises, using adapted standing rowing machines, for example. The idea is that once the nerve fibres had been 'woken up' by the stimulation, the exercises help re-train them to send and receive impulses. 'The electricity isn't being used to directly move the muscles but instead find and recruit nerve fibres, with some of them responding better than others to different energies,' says Mr Baxter. Part of the aim of the trial was to find the best level of stimulation to use. It's thought doing this over a sustained period – each participant had 120 two-hour sessions over a year – helps to create new pathways in the brain to improve movement, he adds. 'We know that spinal-cord injuries cause reorganisation between groups of cells in the nervous system which control movement, and so this approach was aiming to remedy that by targeting them more precisely,' says Mr Baxter. All the participants found their hand grip, dexterity and trunk control improved, meaning they could position themselves better and move in their wheelchair enough to do everyday activities such as eating at a table. Gains made did not plateau even after a year, which suggests the therapy offers long-term benefits and people might see further improvements if continued. Three participants had their classification of spinal-cord damage changed to reflect their slightly improved function – while another, who was paralysed from the waist down, was able to take her first unsupported steps since 2017. It's hoped that following these results, due to be published in the journal Neuromodulation, the ONWARD ARC-EX System which delivers this therapy – already approved in the US – will be approved for use in Europe and the UK by the end of the year. 'Pathfinder is a very positive step for people with spinal-cord injuries where previously they had little hope of restoration of function or walking and using their hands again,' says Mr Baxter. And, he says, even seemingly small improvements can hugely improve someone's quality of life, which Sarra would heartily agree with. After her accident, Sarra, who runs a farm with husband Adam, 40, in Houghton Conquest, Bedfordshire, realised instantly that she couldn't move. She was flown by air ambulance helicopter to Addenbrooke's Hospital in Cambridge, where X-rays revealed she'd broken a bone in her neck so badly it resembled a 'smashed up digestive biscuit', she recalls a doctor saying. Sarra underwent an eight-hour operation to take bone from her right hip to replace the broken vertebrae, stabilise her spine and support her head. She was put into an induced coma for two months before being moved to the National Spinal Injuries Centre in Buckinghamshire in December 2018. Sarra finally went home in March 2020 – after 18 months in hospital – having spent much of her time strapped to a bed unable to move her head. The accident also affected her bowel and bladder function. 'I went home in a wheelchair,' she says. 'I'd been told early on that I would never walk again.' After being discharged, Sarra attended weekly physiotherapy at the Neurokinex centre, a not-for-profit organisation providing rehabilitation for people with paralysis in Hemel Hempstead. It was through them she was invited to be part of the Pathfinder trial, which began in March 2021. 'I was keen to try anything,' says Sarra. 'When I was connected to the machine and it was switched on, I'd feel a tingling pins and needles-type of sensation.' At the same time, she did exercises focused on her arms, hands and core. This included 'using a standing frame that supported me in an upright position, I could use a hand bike – where I'd turn pedals with my hands – or lift light dumbbells, for instance'. Sarra hoped for 'little wins', she says: 'I wanted to be able to hold and sip a hot drink from a normal cup without using a straw, which I can now do. 'I can brush my daughter Isla's hair too – but, annoyingly, I can't brush my own as I can't lift my arms high enough. Best of all, I can now sit at the dinner table with my family and feel normal.' Tara Stewart, chair of trustees at the UK charity Spinal Research, which funded the study, and who was paralysed from the chest down after falling from a horse in 2015, believes it is 'a gamechanger'. 'When I had my injury, we were told that a spinal-cord injury was incurable,' she says. 'We now have this system that restores some function. It demonstrates that a spinal-cord injury isn't incurable and at the very least is improvable,' says Tara, who was also on the trial but did not experience any major changes. Mr Baxter is now running a trial called ImPRESS at the Royal National Orthopaedic Hospital to see if electrically stimulating the base of the spinal cord after an injury can improve bladder and bowel function – as the majority of patients with spinal-cord injury experience significant loss of control of these. 'People can develop recurrent urinary or kidney infections that can cause complications and, in some cases, prove fatal,' he adds. For the trial, 18 paralysed people with bladder and bowel problems will have an electrode, attached to a small battery, implanted under the skin at the base of their spinal cord, where it will deliver electrical impulses to the spinal nerves that control the bowel and bladder. Participants will then carry out 12 weeks of daily pelvic floor exercises. The results will be published next year. Later this month Sarra will be pushed and hauled up Snowdon in her wheelchair by her team of 16 helpers, including family and friends, to fundraise for Back Up, a charity which transforms people's lives after spinal-cord injury. 'Going up Snowdon is something I would never have contemplated before the trial,' she says. 'But the treatment has given me the ability and the confidence to try more things.'
Daily Mail
an hour ago
- Daily Mail
Gel used to smooth out facial wrinkles could be used to treat dry mouth after scientists grow saliva gland in a dish
A gel normally used to smooth out facial wrinkles could also help millions of people who suffer with chronic dry mouth. The gel – hyaluronic acid – is a viscous substance that occurs naturally in the body, helping to lubricate joints, keep skin moist and stop the eyes from drying out. In recent years, man-made versions of the jelly-like material have become a popular cosmetic treatment among those seeking younger-looking skin – making it look plump and banishing unsightly lines. Now a team of scientists have found that synthetic hyaluronic acid is also the perfect environment for growing the cells that release saliva in our mouths. It's the first time that fully functioning cells like this have been grown outside the body – and it's hoped the breakthrough, reported in the International Journal of Oral Science last month, will lead to a new treatment of lab-grown cells that can be transplanted into the mouths of patients suffering persistent dry mouth. The average healthy adult produces up to two litres of saliva every day, which most people swallow without noticing. But up to ten million people in the UK suffer from dry mouth – known as xerostomia – when salivary glands under the tongue and around the jaw don't produce enough saliva. This is often temporary but for some people, dry mouth can become a chronic condition that severely affects their quality of life. Causes range from nasal infections and diabetes to certain medications (including decongestants) and simply not drinking enough fluids, because 99 per cent of saliva is water. Studies have also shown salivary gland cells become less efficient as we age, and no longer produce saliva and enzymes. Patients who have undergone radiotherapy treatment for head and neck cancers, which can damage the glands permanently, are often the most affected. Up to 90 per cent of them develop permanent damage to the salivary glands and dry mouth. Current treatments for dry mouth range from over-the-counter sprays and pastilles that stimulate saliva production, to artificial saliva – usually available only on prescription. But in patients whose salivary glands have been damaged or destroyed, there is little that doctors can offer for effective symptom relief. The hope is that using hyaluronic acid to grow new salivary gland cells and then transplanting them into the mouth could be a better solution – in much the same way that skin is grafted on to wounds or burns to boost healing. Researchers at McGill University in Canada took a small number of human acinar cells – which produce saliva – and placed them in a hyaluronic acid gel in a petri dish. Within a week, the cells started to form into large round clusters that mimicked the appearance of human salivary glands. After two weeks, the cells were still replicating and were metabolically active – for example, producing all the proteins they needed to stay alive and to stimulate the secretion of saliva. The cells also produced the digestive enzyme alpha-amylase, which is important for stimulating the production of saliva. Previous attempts to grow these acinar cells in the lab have had little success, as they don't thrive on the type of 'scaffolds' normally used to regrow tissue – such as collagen. The make-up of salivary glands is also complex, with many specialised cells that are difficult to replicate and grow. Simon Tran, a professor of dentistry at McGill University, who led the research, said it was 'a significant step forward'. 'This study demonstrates that by fine-tuning [hyaluronic acid] gel composition, we can closely replicate the native environment of salivary acinar cells. 'These engineered salivary cells could potentially be delivered via injection directly into the patient's damaged salivary gland, acting much like a graft to restore function.' But he stressed that it's not yet clear if a one-off injection would suffice, or whether repeat treatments might be necessary to maintain healthy saliva production. Commenting on the findings, Austen Smith, a consultant oral and maxillofacial surgeon at Sheffield and Barnsley NHS Foundation Trusts, said the new research is a 'valuable move forward to helping damaged tissue heal to its maximal potential'. And Caroline Geraghty, a specialist information nurse at Cancer Research UK, said: 'It would be a real breakthrough if people could regain full function in their own salivary glands one day so they don't have to rely on temporary fixes.' But she warned larger human trials are needed to see if the gel jabs are safe and effective.
Telegraph
an hour ago
- Telegraph
America is hijacking Britain's hopes of a tech revolution
With its thatched cottages, 11th-century church and grade-II listed buildings, Harwell appears to be the quintessential Oxfordshire village. A brisk stroll through the nearby fields, however, and you will soon find yourself in the beating heart of Britain's scientific community. Harwell Campus, previously a Second World War airfield base for bomber squadrons and gliders, is home to 7,500 scientists and £3bn worth of technological infrastructure. A vast spherical building housing the Diamond Light Source, a powerful particle accelerator, dominates much of the campus. Yet the hub is also home to the UK's National Quantum Computing Centre. This 40,000 sq ft facility, opened by science minister Lord Patrick Vallance last year, is designed to hold 12 cutting-edge quantum computers. These machines, Lord Vallance said in October, would help 'solve some of the biggest challenges we face, whether it's delivering advances in healthcare, enhancing energy efficiency, tackling climate change, or inventing new materials'. The centre is integral to Oxford's hope of succeeding in the global race to crack quantum computing, as it competes with tech giants from both the US and China. These quantum machines should, the theory goes, be able to outperform classical computers many times over by relying on the principles of quantum mechanics. However, it appears the rise of Oxford as a quantum hub has not gone unnoticed. 'Had to sell to America' Last week, a 60-person start-up called Oxford Ionics was sold in a $1bn (£730m) deal to US rival IonQ, a $10bn US-listed quantum giant. The takeover, made up almost entirely of the company's shares, landed Chris Ballance and Tom Hart, Oxford Ionics's founders, a paper fortune of $180m. Driving the deal were breakthroughs in developing 'trapped ion' quantum semiconductors, as Oxford Ionics developed chips that were twice as powerful as their rivals and less prone to errors. For a start-up founded in a basement in Oxford, the deal represented quite the outcome. Niccolo de Masi, chief executive of IonQ and a Cambridge University graduate, claimed the deal would create a company 'head and shoulders' above its rivals. He also stressed that Oxford would become IonQ's 'global R&D hub'. However, the deal has renewed questions over whether Britain has the ability to scale cutting-edge start-ups to help them compete on the global stage. 'Oxford Ionics epitomises British innovation,' said Henry Lee, a strategist at the Tony Blair Institute for Global Change said last week. 'Brilliant Oxford research. Great early backing. Promising tech. But when it came time to scale? Had to sell to America.' Founders in the nascent quantum sector have similarly mixed feelings about the deal. Sebastian Weidt, the chief executive of Universal Quantum, says the sale was a 'testament to the amazing foundations we have in quantum computing in the UK'. However, he adds it was also an 'example of a long list of companies failing to achieve escape velocity independently in the UK'. Inflection point Britain was an early mover in quantum technology. In 2014, under David Cameron's coalition, the government earmarked £1bn in state funding for UK scientists and experts in quantum. Rishi Sunak renewed this pledge in 2023 by promising £2.5bn over the coming decade. This helped fund years of learning, as most quantum computers have so far only been useful for esoteric research and experiments, such as complicated maths problems with little practical use. Yet some technology leaders now believe quantum computing technology is at an inflecion point. This includes Jensen Huang, chief executive of $3.5 trillion tech giant Nvidia, who said last week said useful quantum computers were 'within reach'. Inevitably, this has posed questions about whether Britain is ready to capitalise. Late last year, Peter Kyle, Secretary of State for Science, announced £100m to fund five quantum hubs in the UK. Another £121m was set aside in April. However, industry insiders fear this falls short of the amount industry had expected under the £2.5bn strategy set out by Sunak. Ashley Montanaro, co-founder of Bristol start-up Phasecraft, says: 'Delivery of this funding has lagged behind – especially on the software side. 'It's no surprise that UK quantum companies are looking at opportunities beyond these shores.' Oxford Ionics is not the only UK quantum business bought out by a larger US counterpart in recent years. In 2021, Psiquantum, one of the most promising quantum companies founded by Bristol University professor Jeremy O'Brien, moved to Silicon Valley to secure funds. It is now in the process of raising funds at a $6bn valuation. That same year, another start-up called Cambridge Quantum Computing agreed to merge with a unit of US giant Honeywell. Much of its team is now based in the US. Race for quantum supremacy Some investors say gaining access to later-stage funding remains a challenge for European businesses in cutting-edge 'deep tech' sectors like quantum. Hermann Hauser, founding partner of Amadeus Partners and an investor in Oxford Ionics, says: 'Finding enough money for European scale-ups is our number one problem.' Rob Jesudason, chief executive of Serendipity Capital, an investor in Quantinuum, says the UK 'still lacks' the 'deep tech-orientated capital to scale these organisations'. Not everyone agrees, including Hussein Kanji, of investment firm Hoxton Ventures, who says that 'too many of us worry that we sell our best companies prematurely'. Meanwhile, Steve Brierley, chief executive of quantum business Riverlane, insists that the Oxford Ionics deal is a 'sign that our quantum sector is maturing and attracting serious international attention'. Rather than this being a problem, he says, 'that is something to be proud of and to build on'. Ballance, of Oxford Ionics, adds that Britain has actually done well to retain such a large proportion of its quantum talent over the past decade. Without the UK championing the technology, he says he would have taken his company to the US a decade ago. Instead, he has built a $1bn business from its base in Oxford, which he says will continue to house its main research centre. Similarly, IonQ's De Massi claims a UK-US tie-up is no bad thing, particularly as the West seeks to defeat China in the race for quantum supremacy. 'We are the best chance at beating China in the quantum space race,' says De Masi. 'This is critical to UK and US national economic security. 'We have to beat those other guys together.'
